Literature DB >> 12512073

Total enantioselective synthesis and in vivo biological evaluation of a novel fluorescent BODIPY alpha-galactosylceramide.

Yen Vo-Hoang1, Laurent Micouin, Catherine Ronet, Gabriel Gachelin, Martine Bonin.   

Abstract

Natural killer T (NKT) cells are a distinct subset of mature lymphocytes endowed with features of activated and regulatory T cells. alpha-Galactosylceramides (alpha-GalCers), the synthetic prototype of which is KRN7000, are the only natural reagents recognised by the T-cell receptor of NKT cells. The alpha-GalCer-activated NKT cells promptly release IFN gamma and IL-4 (IFN=interferon; IL=interleukin) and undergo apoptotic death within hours. In mice, activated NKT cells are responsible for antitumour activity and protection against autoimmune diseases. KRN7000 can thus be considered as the root of a family of novel immunoregulatory drugs. To get insights into the in vivo behaviour of alpha-galactosylceramides, an original fluorescent derivative has been prepared by following a convergent synthetic scheme. This strategy allows the introduction of different acyl chains, carbohydrate residues and various labels in the final steps of the synthesis. The fluorescent BODIPY probe derived from a versatile glycolipid precursor is as active as KRN7000 for inducing apoptosis of liver NKT cells. Fluorescence was detected in peritoneal macrophages and splenic antigen-presenting cells, in Kupffer-like cells in the liver, but not in lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12512073     DOI: 10.1002/cbic.200390009

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  7 in total

1.  Highly water-soluble neutral BODIPY dyes with controllable fluorescence quantum yields.

Authors:  Shilei Zhu; Jingtuo Zhang; Giri Vegesna; Fen-Tair Luo; Sarah A Green; Haiying Liu
Journal:  Org Lett       Date:  2010-12-22       Impact factor: 6.005

2.  CD1d-restricted NKT cells modulate placental and uterine leukocyte populations during chlamydial infection in mice.

Authors:  Mohamed Habbeddine; Philippe Verbeke; Christiane Delarbre; René Moutier; Stéphane Prieto; David M Ojcius; Colette Kanellopoulos-Langevin
Journal:  Microbes Infect       Date:  2013-08-31       Impact factor: 2.700

3.  Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect.

Authors:  Xiangming Li; Jing Huang; Akira Kawamura; Ryota Funakoshi; Steven A Porcelli; Moriya Tsuji
Journal:  Vaccine       Date:  2017-05-05       Impact factor: 3.641

4.  A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity.

Authors:  Vincent Lombardi; Philippe Stock; Abinav K Singh; Jerome Kerzerho; Wen Yang; Barbara A Sullivan; Xiangming Li; Takayuki Shiratsuchi; Nathan E Hnatiuk; Amy R Howell; Karl O A Yu; Steven A Porcelli; Moriya Tsuji; Mitchell Kronenberg; S Brian Wilson; Omid Akbari
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

5.  Colocalization of a CD1d-Binding Glycolipid with a Radiation-Attenuated Sporozoite Vaccine in Lymph Node-Resident Dendritic Cells for a Robust Adjuvant Effect.

Authors:  Xiangming Li; Akira Kawamura; Chasity D Andrews; Jessica L Miller; Douglass Wu; Tiffany Tsao; Min Zhang; Deena Oren; Neal N Padte; Steven A Porcelli; Chi-Huey Wong; Stefan H I Kappe; David D Ho; Moriya Tsuji
Journal:  J Immunol       Date:  2015-08-07       Impact factor: 5.422

Review 6.  Fluorescently labelled glycans and their applications.

Authors:  Hongbin Yan; Ravi Shekar Yalagala; Fengyang Yan
Journal:  Glycoconj J       Date:  2015-08-04       Impact factor: 2.916

7.  Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.

Authors:  Peter J Jervis; Paolo Polzella; Justyna Wojno; John-Paul Jukes; Hemza Ghadbane; Yoel R Garcia Diaz; Gurdyal S Besra; Vincenzo Cerundolo; Liam R Cox
Journal:  Bioconjug Chem       Date:  2013-03-19       Impact factor: 4.774

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.